Enzyme replacement therapy in Gaucher's and Fabry's disease
- PMID: 404951
Enzyme replacement therapy in Gaucher's and Fabry's disease
Abstract
Glucocerebrosidase and ceramidetrihexoside-alpha-galactosidase were obtained in a high degree of purity from human placental tissue. The enzymes were infused in Gaucher and Fabry patients, respectively. Following the administration of the proteins to supplement the genetically determined deficiencies, there resulted a specific reduction in the accumulated hlycolipids in the circulation and liver. These results indicate that enzyme replacement may provide hope for the clinical treatment of these disorders.
Similar articles
-
Investigations in enzyme replacement therapy in lipid storage diseases.Fed Proc. 1975 Apr;34(5):1310-5. Fed Proc. 1975. PMID: 804420
-
[Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].J Soc Biol. 2002;196(2):175-81. J Soc Biol. 2002. PMID: 12360746 Review. French.
-
Prospects for enzyme replacement therapy in Gaucher disease.Prog Clin Biol Res. 1982;95:669-80. Prog Clin Biol Res. 1982. PMID: 7122643 No abstract available.
-
Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration.Proc Natl Acad Sci U S A. 1977 Aug;74(8):3560-3. doi: 10.1073/pnas.74.8.3560. Proc Natl Acad Sci U S A. 1977. PMID: 269414 Free PMC article.
-
The lipid storage diseases: new concepts and control.Ann Intern Med. 1975 Feb;82(2):257-61. doi: 10.7326/0003-4819-82-2-257. Ann Intern Med. 1975. PMID: 163609 Review.
Cited by
-
Metabolic syndromes with dermatologic manifestations.Clin Rev Allergy. 1986 Feb;4(1):101-24. doi: 10.1007/BF02991190. Clin Rev Allergy. 1986. PMID: 3516355 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical